Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.34 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844164 | 0.87 | DUT (0.34) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3363163 | 0.85 | CA12 (0.35) | CA12CA1CA2CA9CA14 | |
| SCHEMBL13929076 | 0.78 | CA12 (0.30) | CA12CA1CA2CA9CA14 | |
| SCHEMBL348892 | 0.77 | ALDH1A1 (0.48) | S1PR4LMNATDP1L3MBTL1MAPT | |
| SCHEMBL2151914 | 0.75 | ALDH1A1 (0.45) | S1PR4LMNAGAAMAPTALDH1A1 | |
| SCHEMBL30958030 | 0.75 | TACR2 (0.40) | LMNAGAATDP1L3MBTL1MAPT | |
| SCHEMBL31162886 | 0.73 | ALOX5AP (0.34) | HTR2AHTR2CLMNAGAATDP1 | |
| SCHEMBL5644897 | 0.73 | CLCN2 (0.38) | HTR2AHTR2CLMNAGAATDP1 | |
| SCHEMBL3363545 | 0.72 | HTR2A (0.36) | HTR2AHTR2CGAATDP1L3MBTL1 | |
| SCHEMBL604683 | 0.72 | DUT (0.34) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996590-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1996590-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007104664-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104664-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | CA12 4435/4885CA1 4448/4885CA2 3595/4885 |
| US-20070213341-A1 | Spiroindolinone derivatives | MKI67, PKD1, RCC2 | CA12 3220/4885CA1 4057/4885CA2 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.